Health Sciences Institutional Review Board (HSIRB)

Contact Us

HSIRB Site Index

The HSIRB Site is presented in 5 Sections. You may "click on a section title" to jump to that section or just scroll down to browse:

  1. General Information
  2. Guidelines/Requirements
  3. Forms and Templates (All HSIRB Forms and Templates)
  4. Useful Resources and Links
  5. For HSIRB Members Only

TopSECTION 1: GENERAL INFORMATION

Print PDF of Entire Section
About the HSIRB
  • Types of Projects the HSIRB Reviews
  • Office Location and Hours
  • Staff List
  • Contact Information
HSIRB Meeting Dates
Submission Deadline Dates and How To Submit Materials For HSIRB Review
Quality Assurance / Quality Improvement Program
  • What is the UB HRPP QA/QI Program
  • Site Visits
  • HRPP and IRB Training Wokshops
  • HRPP Topics Newsletter
  • Contact Information
UB Federalwide Assurance (FWA)
HRPP Topics / Newsletters
What's New
HSIRB Membership List
HSIRB Training for Researchers

TopSECTION 2: GUIDELINES/ REQUIREMENTS

Print PDF of Entire Section
Advertising for Research Participants
  • What are "Advertising and Recruitment Materials"?
  • What to submit to the IRB
  • When and How to submit advertising and recruitment materials for approval
  • Video or Audio Advertisements
  • Internet Advertisements
  • Content Requirements
Amending/Making Changes to an Approved Research Project
  • What amendments or changes must be submitted for HSIRB approval?
  • “What and “How” to submit amendments/changes to the HSIRB
  • HSIRB review of amendments/changes to approved projects
Case Reporting
Completed / Closed Studies
  • When to notify the HSIRB
  • What to submit to the HSIRB
  • How to notify the HSIRB
  • Investigator responsibilities after study closure
Conflicts of Interest (Financial): Annual Requirements for PIs and co-PIs
Continuing Review
  • Overview
  • Level of Review: Expedited or Full Board Review
  • Investigator Responsibilities for Continuing Review of Projects
  • What and When to Submit for Continuing Review
  • How to submit documents to the HSIRB
Data and Safety Monitoring
  • Overview
  • Elements of a Data and Safety Monitoring Plan (DSMP)
  • Determining the Appropriate Level of Monitoring
  • Data Monitoring Committees (DMCs) and Data and Safety Monitoring Boards (DSMBs)
  • For Pharmaceutical Clinical Trials
  • NIH Sponsored Research
  • IRB Review of DSMPs and DSMB/DMC summaries and reports at Continuing Review
  • Additional Information
Education and Training
  1. UB HRPP Required Training:
    • Who must complete the CITI training?
    • What is CITI training?
    • What are the initial training requirements?
    • What if I completed equivalent CITI training at another institution?
    • What are the continuing training requirements?
    • How do I access CITI training courses?
  2. CITI Optional Courses and Optional Modules
    • What are CITI Optional “Courses” and Optional “Modules”?
  3. HRPP and IRB Training Workshops available for researchers
Exemption Requests
FDA REGULATED PRODUCTS: RESEARCH INVOLVING INVESTIGATIONAL DRUGS, AGENTS, BIOLOGICS, AND DEVICES
  • Overview
  • Investigational new drug (IND)
    • B-1. Overview
    • B-2. Types of IND Applications
    • B-3. Phases of a Clinical Trial
    • B-4. Requirements for Submission of an IND Application to the FDA for Research Involving Drug or Biologics that Have Not Yet Reached the Market
    • B-5. Clinical Investigations of Marketed Drugs Not Requiring Submission of an IND Application
    • B-6. Research Involving Combinations of FDA Approved Drugs, Agents or Biologics
    • B-7. Investigator Responsibilities for Research Involving Investigational Drugs, Agents and Biologics
    • B-8. Investigator Responsibilities for Storage, Handling, and Dispensing of Investigational Drugs, Agents, and/or Biologics
    • B-9. Emergency Use of an Investigational Drug or Biologic
    • B-10. Emergency Exemption from Prospective IRB Approval
    • B-11. Exception from Informed Consent Requirement
    • B-12. Expanded Access to Investigational Drugs
    • B-13. Communication with Hospital-Based Pharmacies
  • Investigational Device Exemption (IDE)
    • C-1. Overview
    • C-2. Investigational Device Exemption (IDE)
    • C-3. Exemptions from Obtaining an IDE
    • C-4. Significant Risk vs. Non-Significant Risk Devices
    • C-5. Investigator Responsibilities for Studies Involving Investigational Devices
    • C-6. Responsibilities of Investigators Who Also Sponsor the Research
    • C-7. Investigator Responsibilities Involving Unanticipated Adverse Device Effects
    • C-8. IRB Review of Investigational Devices in Determining SR/NSR
    • C-9.Investigator Responsibility for Maintaining the Distinction Between Research and Therapy
    • C-10.Concurrence of FDA, Sponsor and IRB Determinations for SR/NSR
  • Humanitarian Use Devices (HUDs)
    • D-1. Overview
    • D-2. Investigator Responsibilities for HUDs
    • D-3. Additional Reporting Requirements for Serious Events/Problems (SEPs) Involving HUDs
    • D-4. IRB Review of HUD Use
  • Emergency Use of Unapproved Medical Devices
    • E-1. Overview
    • E-2. Requirements for Emergency Use
    • E-3. After-use Procedures
    • E-4. Exception from Informed Consent Requirement for Medical Devices
    • E-5. Exception from Informed Consent for Planned Emergency Research
    • E-6. Investigator Responsibilities for Conducting Planned Emergency Research
    • E-7. IRB Review of Planned Emergency Research
  • IRB Responsibilities for Emergency Use of FDA Regulated Products
Fees Associated with IRB Review of a Commercially Sponsored Research Project
Forms and Templates (All HSIRB Forms and Templates)
HIPAA (Health Insurance Portability and Accountability Act): Guidelines/Forms/Templates
  • HIPAA Guidelines
  • HIPAA Forms
    • Worksheet
    • Authorization
    • De-Identification
    • Full Waiver
    • Partial Waiver
Informed Consent Process
  1. Overview
  2. Requirements for Informed Consent
    • B1. Elements of consent: What must be said about the research
      • Basic Elements
      • Additional Elements
      • Specific FDA requirements
    • B2. Providing enrolled subjects with new information
  3. Who may obtain consent, permission, and assent?
  4. How and where to obtain consent
  5. Documentation of consent
    • E1. Overview
    • E2. Signature Requirements
      • The Subject or LAR
      • Person Obtaining consent
      • A Witness
      • Time of Consent
      • PI Signature
  6. Who Gets a Copy of the Signed Consent Document(s)?
  7. What Consent Documents Must be Retained in the Study Files
  8. Reporting Missing Signatures or Dates and Other Consent Irregularities
  9. Waivers of Consent and Waivers of Documentation of Consent
    • I1. Waiver of consent
    • I2. Waiver of written documentation of consent
  10. Parental Permission and Child Assent
    • J1. Definitions
    • J2. Overview
    • J3. Documentation of permission of parents/guardians
    • J4. Assent of the child
    • J5. Documentation of child assent
    • J6. Waiver of parental/guardian permission
    • J7. Waiver of child assent
    • J8. LARs for minors in New York State
    • J9. Minors in NYS who may be able to give legally effective informed consent
    • J10. When a child reaches the legal age of consent while enrolled in a study
    • J11. Research involving wards of the State
  11. Which consent document formats/templates to use
    • K1. HSIRB formats/templates
    • K2. Sponsor-prepared templates
  12. Special consenting situations
    • L1. Non-English consents
    • L2. Illiterate English-speaking individuals
    • L3. Physically incapacitated individuals
    • L4. Adult decisionally incapacitated individuals
      • Capacity assessment
      • Legally authorized representatives (LAR)
      • Documentation of LAR consent
      • Assent by decisionally incapacitated adult subjects
      • Consent of adult subjects who regain capacity
      • Anticipated loss of decisional capacity by adult subjects enrolled in research
    • L5. Genetic research
    • L6. Pregnant women or fetuses prior to delivery
    • L7. Neonates
    • L8. Students, employees, and others in subordinate positions
Leaving the Institution (When Principal Investigators Leave)
New/Initial Submissions:
  • Expedited Review
    • Overview
    • What to submit
    • How to submit
  • Full Board Review
    • Overview
    • What to submit
    • How to submit

(See also Exemption Requests)

Privacy and Confidentiality
  • Privacy vs. Confidentiality – What is the difference?
  • Protecting Participant Privacy Interests
Protocol Requirements
Quality Control Projects
Reportable Events and Problems
  • "On-Site" events/problems
    • Determining "Serious" or "Non-Serious"
    • Reporting "Serious" Events/Problems (SEPs)
    • Requirements for follow-up reports
    • Reporting "Non-Serious" events/problems
  • "Off-Site" SEPs
    • Safety Reports
    • Other types of off-site SEP notifications
    • How to report an off-site SEP
  • PI responsibilities at the time of continuing review
  • PI responsibilities for further reporting of events/problems
Retrospective Chart Reviews
Roswell Park Cancer Institute (RPCI) - Research Agreement
Survey Research
Veteran's Administration WNY (VAWNY) – Research Agreement
Vulnerable Subject Populations
  1. Overview
  2. Research involving Pregnant Women, Human Fetuses and Neonates
    • B1. Overview
    • B2. IRB Requirements for Approval of Biomedical Research Involving Pregnant Women and Fetuses
  3. Research Involving Prisoners
    • C1. Overview
    • C2. If an enrolled subject becomes a “prisoner”
  4. Research Involving Children
    • D1. Overview
    • D2. Wards of the State
  5. Other Groups and Research Situations Requiring Special Consideration
    • E1. Overview
    • E2. Adults Unable to Provide Consent
    • E3. Research in Schools
    • E4. Students, Employees, and Others in Subordinate Positions
    • E5. Economically or Educationally Disadvantaged Persons and Other Groups Requiring Special Consideration
    • E6. Minors in New York State Who May Consent for Themselves

TopSECTION 3: FORMS and TEMPLATES (all HSIRB forms and templates)

  • Amendment Form
  • Annual Disclosure of Significant Financial Interest and Significant Obligations
  • Authorization of Fee Collection for IRB Review of a Commercially Sponsored Research Protocol
  • Closed/Completed Notification Form
  • Continuing Review Application
  • Exempt Status Request Form
  • Expedited Review Form
  • HIPAA Forms
    • Worksheet
    • Authorization
    • De-Identification
    • Full Waiver
    • Partial Waiver
  • HS-1A Application Form
  • HS-1A Multi-Site Addendum Form
  • Informed Consent Templates
    • Consent Document Template
    • Consent Document Template with HIPAA Incorporated
    • Parental Permission Template (includes alternative signature page for participants 14-17 yrs of age)
    • Parental Permission Template with HIPAA Incorporated (includes alternative signature page for participants 14-17 yrs of age)
    • Assent Document Template (for children 7-13 yrs of age)
  • Serious Events And Problems (SEPs)- Initial Report Form
  • Serious Events And Problems (SEPs) - Follow-Up Report Form

TopSECTION 4: USEFUL RESOURCES AND LINKS

General Resources

  • Other UB IRBs that Review Human Subjects Research
    • Children & Youth IRB
    • Social & Behavioral Sciences IRB
  • Office of the Vice President for Research
  • CITI Human Subjects Protection Tutorial
  • Lay Terms for Use in Consent Forms
  • NIH (National Institutes of Health)
  • Tips for Writing an Understandable Consent Document
  • UB HIPAA Web Site
  • UB HRPP Standard Operating Procedures (SOP)
  • UB Sponsored Projects Services (SPS)

Ethical Principles and Guidelines

  • Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research
  • Nuremburg Code

Regulations

  • DHHS Regulations (Department of Health & Human Resources)
    • DHHS 45 CFR Part 46 - Protection of Human Subjects/ Institutional Review Boards
    • OHRP Site (Office for Human Research Protections)
  • FDA Regulations (Federal Drug Administration)
    • FDA 21 CFR Part 50 - Protection of Human Subjects
    • FDA 21 CFR Part 56 - Institutional Review Boards
    • FDA 21 CFR Part 312 – Investigational New Drug Application
    • FDA 21 CFR Part 812 – Investigational Device Exemptions
    • FDA Site (Food and Drug Administration)

TopSECTION 5: FOR HSIRB MEMBERS ONLY

HSIRB Meeting Dates

Reviewer Evaluation and Guidesheets

  • Initial Review
  • Continuing Review
  • Amendment
  • Exempt Status
  • Children
  • Pregnant Women
  • Prisoners
  • Serious Events and Problems (SEPs)
  • Short Form Consent Process
  • Waiver of Consent and Waiver of Documentation of Consent